

Consideraciones especiales en rotavirus, neumococo y meningococo

Dr. Juan Gonzalo Mesa

Referencias bibliográficas:

<https://vacunasaep.org>

Kirkwood CD et al. *The rotavirus vaccine development pipeline. Vaccine* 37 (2019) 7328–7335

http://ais.paho.org/hip/viz/ed_meningo_esp.asp

Burnett E et al. *Real-world effectiveness of rotavirus vaccines, 2006–19: a literature review and meta-analysis. Lancet Glob Health* 2020; 8: e1195–202

Marquez L. *Ch-88 Meningococcal Disease en Feigin and Cherry's Textbook of Pediatric Infectious Diseases 8th Ed. 2018*

Clinical Infectious Diseases 2008; 46:1793–4

<https://ourworldindata.org/child-mortality>

Cortesía Dr. German Camacho. *Elaboración propia a partir de la Fuente: Instituto Nacional de Salud Grupo de Microbiología. Reporte SIREVA II Colombia 1994-2018. Disponible en www.ins.gov.co*

Cortesía: Dr Germán Camacho Red NeumoColombia

World Health Organization. (2021). *Considerations for pneumococcal conjugate vaccine (PCV) product choice. World Health Organization. <https://apps.who.int/iris/handle/10665/344915>*